Iodine-131(131I)-MIP-1095 is a PSMA-targeted small-molecule inhibitor radionuclide therapy developed by Molecular Insight Pharmaceuticals, Inc. It was one of the first agents used in radiopharmaceutical therapy against prostate cancer. This evidence concerns the gene FOLH1 and Familial prostate cancer.